Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA). MS-RDA isolated 111 DNA fragments derived from CpG islands (CGIs), and 35 of them were from CGIs in the 5 0 regions of known genes. Methylation-specific PCR (MSP) of the CGIs in seven pancreatic cancer cell lines and two pancreatic ductal epithelial cell lines showed that 27 CGIs in the 5 0 regions were aberrantly methylated in at least one of the cancer cell lines. Quantitative reverse-transcription-PCR analysis showed that downstream genes of all the CGIs were either not expressed or only very weakly expressed in cancer cell lines with the aberrant methylation. In the pancreatic ductal epithelial cell lines, 18 genes were expressed at various levels, and nine genes were not expressed at all. Treatment of a cancer cell line with a demethylating agent, 5-aza-2 0 -deoxycytidine, restored the expression of 13 genes, RASGRF2, ADAM23, NEF3, NKX2-8, HAND1, EGR4, PRG2, FBN2, CDH2, TLL1, NPTX1, NTSR1 and THBD, showing their silencing by methylation of their 5 0 CGIs. MSP of 24 primary pancreatic cancers showed that all these genes, except for THBD, were methylated in at least one cancer. Some of those were suggested to be potentially involved in pancreatic cancer development and progression.
Aberrantly methylated DNA fragments were searched for in human pancreatic cancers, using the genome scanning technique: methylation-sensitive-representational difference analysis (MS-RDA). MS-RDA isolated 111 DNA fragments derived from CpG islands (CGIs), and 35 of them were from CGIs in the 5 0 regions of known genes. Methylation-specific PCR (MSP) of the CGIs in seven pancreatic cancer cell lines and two pancreatic ductal epithelial cell lines showed that 27 CGIs in the 5 0 regions were aberrantly methylated in at least one of the cancer cell lines. Quantitative reverse-transcription-PCR analysis showed that downstream genes of all the CGIs were either not expressed or only very weakly expressed in cancer cell lines with the aberrant methylation. In the pancreatic ductal epithelial cell lines, 18 genes were expressed at various levels, and nine genes were not expressed at all. Treatment of a cancer cell line with a demethylating agent, 5-aza-2 0 -deoxycytidine, restored the expression of 13 genes, RASGRF2, ADAM23, NEF3, NKX2-8, HAND1, EGR4, PRG2, FBN2, CDH2, TLL1, NPTX1, NTSR1 and THBD, showing their silencing by methylation of their 5 0 CGIs. MSP of 24 primary pancreatic cancers showed that all these genes, except for THBD, were methylated in at least one cancer. Some of those were suggested to be potentially involved in pancreatic cancer development and progression. Oncogene Keywords: methylation; pancreatic cancer; CpG island; silencing Pancreatic cancer is one of the most refractory neoplasms, with the average 5-year survival being less than 20% (Jemal et al., 2003) . In addition to the anatomical location of the pancreas that makes early detection of pancreatic cancers very difficult, several genetic and biological characteristics, such as the presence of severe chromosomal instability and the strong involvement of stromal tissues, are considered to underlie their poor prognosis (Bardeesy and DePinho, 2002) . As genetic alterations in pancreatic cancers, mutational activation of K-ras (90%) (Almoguera et al., 1988) and inactivation of p16 (80%), p53 (50-70%), and SMAD4/DPC4 (50%) by mutations and allelic losses (Caldas et al., 1994; Hahn et al., 1996; Rozenblum et al., 1997; Wilentz et al., 2000) are wellknown.
Epigenetic alterations are also known to be involved in pancreatic cancers, including inactivation of p16, RARb and TIMP-3 by methylation of promoter CpG islands (CGIs) Merlo et al., 1995; Ueki et al., 2000) . Considering that multiple tumorsuppressor genes are inactivated by methylation in human pancreatic cancers, genome-wide scanning for genes that are inactivated by methylation of promoter CGIs is important. By methylated CpG island amplification/representational difference analysis (MCA/RDA) technique (Toyota et al., 1999) , Ueki et al. (2001) identified seven CGIs differentially methylated in pancreatic cancers. By cDNA microarray analysis of genes whose expressions were induced by a demethylating agent, 5-aza-2 0 -deoxycytidine (5-aza-dC), Sato et al. (2003) identified 11 genes whose promoter CGIs were aberrantly methylated.
In a genome-scanning technique, methylation-sensitive-RDA (MS-RDA) (Ushijima et al., 1997) , unmethylated, CpG-rich regions of the genome can be amplified from two genomes using methylation-sensitive restriction enzymes, such as HpaII, SacII, and NarI, and the two 'amplicons' are compared by RDA (Lisitsyn and Wigler, 1993) . By this strategy, diverse CpG islands in the genome can be scanned (Kaneda et al., 2003) , and genes silenced in human stomach, breast and lung cancers have been identified (Takai et al., 2001; Kaneda et al., 2002; Asada et al., 2003; Miyamoto et al., 2003) . In this study, MS-RDA was applied to human pancreatic cancers.
Isolation of differentially methylated DNA fragments by MS-RDA DNA fragments methylated in a pancreatic cancer cell line, HPAC, but not in an immortalized human pancreatic ductal epithelial cell line, HPDE-4/E6E7 (Furukawa et al., 1996; Liu et al., 1998) , were searched for by three series of MS-RDA, using HpaII, SacII and NarI. A total of 295 DNA fragments were obtained in the three series. By sequencing them using ABI PRISM310 (PE Biosystems, Foster City, CA, USA), 168 DNA fragments were found to be nonredundant. By BLAST search at a GenBank web site, 111 DNA fragments of them were found to be derived from CGIs, and 40 were derived from CGIs in the 5 0 regions of genes (Table 1 ). We selected CGIs that met a criterion described by D Takai and PA Jones (Takai and Jones, 2002) .
From the 40 CGIs in the 5 0 regions of genes, 35 CGIs located in the 5 0 regions of known genes were selected. Their methylation statuses were examined by methylation-specific PCR (MSP) (primer sequences in Supplementary Table 1) using two immortalized human pancreatic ductal epithelial cell lines (HPDE-4/E6E7 and HPDE6-E6E7c7) and seven pancreatic cancer cell lines (American Type Culture Collection, Rockville, MD, USA). CGIs in the 5 0 regions of 27 genes (Figure 1) , RASGRF2, ADAM23, NEF3, OLIG3, FGF14, NKX2-8, SALPR, RAX, RGS17, NGN1, HAND1, SOX5, RGS20, EGR4, ADAMTS19, PRG2, FBN2, HOXC12, CLIP-2, LMX1A, PDE10A, SLC6A2, CDH2, TLL1, NPTX1, NTSR1 and THBD, were methylated in at least one of the seven pancreatic cancer cell lines but not in either of the ductal epithelial cell lines ( Figure 2 ). Most of these genes were identified as aberrantly methylated for the first time in this study, except for three genes, HAND1 and THBD in stomach cancers (Kaneda et al., 2002) , LMX1 in a colon cancer cell line (Paz et al., 2003) , and ADAM23 in breast cancers (Costa et al., 2004) .
Analysis of expression levels of the 27 genes
Expression levels of the 27 genes were analysed by quantitative real-time RT-PCR (primer sequences in Supplementary Table 2) in the two ductal epithelial cell lines and seven pancreatic cancer cell lines (Figure 3 ). Considering that genes with abundant expression have higher chances of being biologically active, the genes were classified into two groups according to their expression levels in the two ductal epithelial cell lines. Six genes, RASGRF2, PRG2, FBN2, CDH2, NTSR1 and THBD, were abundantly expressed in at least one of the two ductal epithelial cell lines, being more than 10 À3 molecules/GAPDH molecules. In all, 11 genes, ADAM23, NEF3, OLIG3, FGF14, NKX2-8, HAND1, EGR4, CLIP2, SLC6A2, TLL1 and NPTX1, were expressed at relatively low levels, with 10 À4 and 10
À3
molecules/GAPDH molecules. The remaining 10 genes were not expressed at all in either of the two ductal epithelial cell lines.
The correlation between the expression levels and methylation status in the cancer cell lines was examined. All the genes, except CDH2 and FGF14, were either not expressed or very weakly expressed in cancer cell lines with methylations. CDH2 was expressed in a cancer cell line, BxPC3, in which only methylated DNA molecules were detected by MSP. However, it turned out that, in BxPC3, unmethylated and methylated CpG sites coexisted in the regions for which MSP primers were designed, and that at least partially unmethylated DNA molecules were present (data not shown). FGF14 showed 'expression' that looked discordant with the methylation status in cell lines. However, the expression levels of FGF14 in the brain and testes were 100-times as high as those in the two immortalized ductal epithelial cell lines. This strongly suggested that the apparent FGF14 expression in the pancreatic cancer cell lines and two immortalized ductal epithelial cell lines did not reflect functional levels but was simple leaky expression.
Demethylation and re-expression by 5-aza-dC
To examine the role of methylation of the 5 0 CGIs in the loss of gene expression, cancer cells were treated with 5-aza-dC. For all of the six genes with abundant expression, demethylation of their 5 0 CGIs induced their re-expression in cancer cell lines that had only methylated DNA molecules (Figure 3 ). In contrast, reexpression was observed only in seven (ADAM23, NEF3, NKX2-8, HAND1, EGR4, TLL1 and NPTX1) of the 11 genes with low expression. These results showed that methylation of the 5 0 CGIs of the six and seven genes, 13 genes in total, caused their silencing. Since the approach in this study was based on DNA methylation, we were able to identify silencing of genes with low expression levels. As exemplified by p16 (Figure 3 , panel R), some of genes with low expression levels are still important for carcinogenesis.
Analysis of aberrant methylation in primary human pancreatic cancers
In total, 24 primary pancreatic cancers were collected from patients undergoing pancreatectomy with informed consents, and DNA was extracted from the frozen samples. All the cancers were diagnosed as invasive ductal adenocarcinomas (detailed clinical information in Supplementary Table 3 ). For 18 of the 24 cases, macroscopically normal regions were present in the resected specimens, and noncancerous pancreatic tissues were obtained. Methylation of the 27 5 0 CGIs was analysed by MSP in the 24 cancer and 18 noncancerous samples. Among the 13 genes that were silenced by methylation of 5 0 regions, methylation was observed for 12 genes: RASGRF2 (17%), ADAM23 (29%), NEF3 (63%), NKX2-8 (13%), HAND1 (8%), EGR4 (4%), PRG2 (63%), FBN2 (75%), CDH2 (29%), TLL1 (13%), NPTX1 (13%) and NTSR1 (8%). Among the four genes that were expressed in the two immortalized ductal epithelial cell lines but whose expression was not restored by 5-aza-dC, methylation Of the 40 CGIs flanked by the DNA fragments, 35 CGIs were analysed for their methylation status, and 27 CGIs were found to be methylated in one or more cell lines. Expression analysis of the 27 downstream genes showed that 17 of them were expressed **abundantly or *slightly in pancreatic ductal epithelial cell lines. Treatment with 5-aza-dC indicated that 13 of them (shown by w) were silenced in cancer cell lines. z Methylation in noncancerous tissue was observed. ND: not done in at least one primary cancer was observed for three genes; CLIP2 was the exception. Of the 10 genes that were not expressed in the two immortalized ductal epithelial cell lines, methylation was observed for nine. Of the 27 aberrantly methylated 5 0 CGIs, only those of OLIG3 and RAX showed methylation in the 18 noncancerous samples. Methylation is reported to be often detected even in noncancerous samples (Ueki et al., 2001) . The low incidence in this study was in contrast, and was considered to be due to the region analysed and to the analytical method employed. To search for a region in a CGI that is consistently unmethylated in the two immortalized ductal epithelial cell lines, we tried multiple regions in the CGI. For MSP, we first determined the number of PCR cycles that would produce a minimal band with 100%-methylated DNA (DNA treated with SssI-methylase), and four more cycles were added for the test samples.
Included among the 12 genes that were silenced in pancreatic cancer cell lines and methylated in primary pancreatic cancers were genes that can be potentially involved in pancreatic cancer development and progression. RASGRF2 was deleted in two cell lines (BxPC3 and Capan-2, Figure 2 ). RASGRF2 has been reported to be involved in H-Ras signalling (Arozarena et al., 2004) , and its expression to be decreased in rat mammary carcinomas (Qiu et al., 2003) . Frequent epigenetic silencing of ADAM23 was recently reported in breast cancers (Costa et al., 2004) . PRG2 is located on chromosome 2pter-p25, and loss of heterozygosity at this locus is reported in pancreatic cancers (Griffin et al., 1994) . Its shorter variant is highly expressed in cells undergoing apoptosis due to p53 overexpression (Horikoshi et al., 1999) , and its longer variant, MG50, is strongly immunogenic to human cytolytic T lymphocytes (Mitchell et al., 2000) . Silencing of the PRG2/ MG50 gene could confer a growth advantage to a cell by allowing it to escape from immune surveillance and/or p53-dependent apoptosis. N-cadherin, coded by CDH2, 0 CGIs whose downstream genes were expressed in the two ductal epithelial cell lines. Methylation statuses were first analysed in seven pancreatic cancer cell lines (1: BxPC3, 2: HPAF-II, 3: Capan-2, 4: MIA PaCa-2, 5: Hs766 T, 6: PANC-1, 7: HPAC) and two immortalized pancreatic ductal epithelial cell lines (8: HPDE6-E6E7c7, 9: HPDE-4/E6E7). 10: SssI-methylated DNA of HPDE-4/E6E7. Then, CGIs methylated in at least one cell line were analysed in 24 primary pancreatic cancers and 18 noncancerous tissues. Results on four representative paired samples are shown here (1-14: N, noncancerous tissue; C, cancer). Genomic DNA was treated with bisulfite as reported (Kaneda et al., 2002) , and was amplified using primer sets specific to methylated and unmethylated genomic DNA (M and U sets, respectively). Closed arrows show bands obtained with the M primer set. Rectangles show regions where no PCR products were obtained using the U or M primer sets, indicating homozygous deletion was recently reported to function in the downstream of the RASSF1A tumor-suppressor gene (Agathanggelou et al., 2003) , and its silencing could confer a growth advantage.
In contrast, genes that are unlikely to be involved in pancreatic cancer development and progression were also present among the 13 silenced genes. NEF3 and NPTX1 are known to be functionally expressed in the brain (Omeis et al., 1996; Julien and Mushynski, 1998) , and EGR4 is functionally expressed in the testes (Tourtellotte et al., 1999) . HAND1 is essential for placental development (Riley et al., 1998) , and TLL1 plays multiple roles in heart development (Clark et al., 1999) . The expression levels of NEF3, HAND1, EGR4, TLL1 and NPTX1 were lower than 1/100 of those in the brain or testes. In addition, 10 genes whose 5 0 CGIs were methylated in pancreatic cancer cell lines were not expressed at all in the two immortalized ductal epithelial cell lines. These suggested that genes with low or no expression tended to be silenced by promoter methylation.
In summary, we identified 27 aberrantly methylated 5 0 CpG islands and 13 genes silenced by methylation of the 5 0 CGIs, and most of them were novel.
Abbreviations CGI, CpG island; MS-RDA, methylation-sensitive representational difference analysis; MSP, methylation-specific PCR; RT-PCR, reverse-transcription-PCR; 5-aza-dC, 5-aza-2 0 -deoxycytidine. Figure 3 Expression levels of the 17 genes and the p16 gene. Expression levels were analysed in the seven cancer cell lines, two pancreatic ductal epithelial cell lines, and cancer cell lines after 5-aza-dC treatment. Those in the brain and testes were also analysed. 1: BxPC3, 2: HPAF-II, 3: Capan-2, 4: MIA PaCa-2, 5: Hs766T, 6: PANC-1, 7: HPAC, 8: HPDE6-E6E7c7, 9: HPDE-4/E6E7. 0, 0.5 and 1 stand for concentrations of 5-aza-dC treatment. cDNA was synthesized from 3 mg of total RNA using a Superscript II kit (Invitrogen) after DNase treatment. The numbers of cDNA molecules were quantified using SYBR Green PCR Core Reagents (PE Applied Biosystems, Foster City, CA, USA) and an iCycler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA), and were normalized to that of GAPDH cDNA molecules. Six genes, RASGRF2, PRG2, FBN2, CDH2, NTSR1 and THBD genes (panels A, I, J, M, P and Q, respectively), were found to be expressed at levels higher than 1/1000 of GAPDH in one or both of the two ductal epithelial cell lines, and the other 11 genes were expressed at low levels in the two ductal epithelial cell lines. The expressions of the six abundantly expressed genes and seven of the 11 weakly expressed genes were restored by 5-aza-dC treatment, demonstrating their silencing by methylation. Results of MSP in 
